Literature DB >> 14629094

Biological implications of bi-directional fetomaternal cell traffic: a summary of a National Institute of Child Health and Human Development-sponsored conference.

D W Bianchi1, R Romero.   

Abstract

OBJECTIVE: The National Institute of Child Health and Human Development (NICHD) held a workshop on 27-28 July 2000 to bring together investigators working in the field of fetomaternal cellular and nucleic acid trafficking with the hope that this would stimulate further research into the biological implications of such phenomena.
METHODS: Invited speakers from all over the world presented their latest (unpublished) data. The conference proceedings were delayed until the present time to allow independent publication of the primary data. RESULTS AND
CONCLUSIONS: Bi-directional fetomaternal trafficking of cells and nucleic acids during pregnancy is now well established, through the use of molecular techniques including conventional and real-time polymerase chain reaction, as well as fluorescence in situ hybridization. In addition, human leukocyte antigen (HLA) is deposited in the skin of pregnant women. Fetomaternal trafficking is increased in some complications of pregnancy, such as pre-eclampsia, polyhydramnios, polymorphic eruption of pregnancy, preterm labor and specific fetal chromosome aneuploidies. Maternal cells and nucleic acids have been documented in umbilical cord blood and in autopsy tissue of non-transfused neonates. Fetal cells persist postpartum and may be associated with the development of disorders such as scleroderma, lichen planus, lupus and thyroid disease. The extent of fetomaternal trafficking may be affected by three generational HLA relationships. Thus, the consequences of pregnancy extend beyond gestation.

Entities:  

Mesh:

Year:  2003        PMID: 14629094     DOI: 10.1080/jmf.14.2.123.129

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  6 in total

1.  MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis.

Authors:  Chunming Ding; Rossa W K Chiu; Tze K Lau; Tse N Leung; Li C Chan; Amy Y Y Chan; Pimlak Charoenkwan; Ivy S L Ng; Hai-Yang Law; Edmond S K Ma; Xiangmin Xu; Chanane Wanapirak; Torpong Sanguansermsri; Can Liao; Mary Anne Tan Jin Ai; David H K Chui; Charles R Cantor; Y M Dennis Lo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

2.  Pregnancy-associated diseases are characterized by the composition of the systemic regulatory T cell (Treg) pool with distinct subsets of Tregs.

Authors:  A Steinborn; E Schmitt; A Kisielewicz; S Rechenberg; N Seissler; K Mahnke; M Schaier; M Zeier; C Sohn
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

4.  A Profile of Dennis Lo, DM, DPhil, FRCP, FRCPath, FRS.

Authors:  Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2018-04       Impact factor: 8.661

5.  Mild-to-moderate foeto-maternal haemorrhage in the third trimester and at term of pregnancy: quantitative determination and clinical-diagnostic evaluation.

Authors:  Fausta Beneventi; Chiara Cavagnoli; Elena Locatelli; Silvia Bariselli; Margherita Simonetta; Gianluca Viarengo; Cesare Perotti; Arsenio Spinillo
Journal:  Blood Transfus       Date:  2017-04-19       Impact factor: 3.443

6.  Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia.

Authors:  Giovanna Ogge; Tinnakorn Chaiworapongsa; Roberto Romero; Youssef Hussein; Juan Pedro Kusanovic; Lami Yeo; Chong Jai Kim; Sonia S Hassan
Journal:  J Perinat Med       Date:  2011-08-17       Impact factor: 1.901

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.